Back to top
more

KaloBios Pharmaceuticals Inc. (HGEN)

(Delayed Data from OTC)

$1.15 USD

1.15
3,762

-0.07 (-6.07%)

Updated May 3, 2019 01:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia

by Zacks Equity Research

Humanigen's (HGEN) shares surge after presenting promising early results of its Precision Approach to Chronic Myelomonocytic Leukemia study of lenzilumab in chronic myelomonocytic leukemia.

Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 3.08% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Liquidia Technologies, Inc. (LQDA) delivered earnings and revenue surprises of 22.22% and 9.55%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 8.67% and 4.69%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Humanigen Inc. (HGEN) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Humanigen Inc. (HGEN) delivered earnings and revenue surprises of -26.47% and 0.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Adicet Bio, Inc. (ACET) delivered earnings and revenue surprises of -24.44% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

LAVA Therapeutics N.V. (LVTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

LAVA Therapeutics N.V. (LVTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Humanigen Inc. (HGEN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Humanigen Inc. (HGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Selecta Biosciences, Inc. (SELB) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Selecta Biosciences, Inc. (SELB) delivered earnings and revenue surprises of 300% and 83.11%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Humanigen (HGEN) Plunges as COVID Study Fails to Meet Goal

by Zacks Equity Research

The NIAID's ACTIV-5/BET-B study evaluating Humanigen's (HGEN) lenzilumab plus remdesivir in hospitalized COVID-19 patients fails to meet the primary endpoint. Stock down.

KaloBios Pharmaceuticals Inc. (HGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of 34.69% and 0.39%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Exact Sciences (EXAS) delivered earnings and revenue surprises of 7.14% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Seattle Genetics (SGEN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Seattle Genetics (SGEN) delivered earnings and revenue surprises of -20.25% and 6.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

KaloBios Pharmaceuticals Inc. (HGEN) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

KaloBios Pharmaceuticals Inc. (HGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

New Strong Sell Stocks for September 14th

by Zacks Equity Research

ATR, FTAI, HGEN, LMB, and MRSN have been added to the Zacks Rank #5 (Strong Sell) List on September 14, 2021.

Implied Volatility Surging for Humanigen (HGEN) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

KaloBios Pharmaceuticals Inc. (HGEN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

KaloBios Pharmaceuticals Inc. (HGEN) delivered earnings and revenue surprises of -160.87% and -98.27%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Humanigen (HGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Emergent (EBS) Beats on Q1 Earnings, Cuts Contract Revenue View

by Zacks Equity Research

Emergent's (EBS) earnings in the first quarter of 2021 beat estimates while revenues miss the same. It lowers guidance for revenues from CDMO services. Stock down.

Is the Options Market Predicting a Spike in Humanigen (HGEN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Do Options Traders Know Something About Humanigen (HGEN) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Humanigen (HGEN) stock based on the movements in the options market lately.

Is a Surprise Coming for Humanigen (HGEN) This Earnings Season?

by Zacks Equity Research

Humanigen (HGEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.